A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer
Clinical trial NCT02831491 · WITHDRAWN
Trial details
- NCT number
- NCT02831491
- Sponsor
- Eli Lilly and Company
- Status
- WITHDRAWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-11-01
- Primary completion
- 2017-07-01
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.